- Datum15.01.2025
- Uhrzeit15:00 - 15:30 Uhr
- Veranstalter
stock3
Thomas May
Moderator
Arcutis Biotherapeutics Inc. Aktie
Verkaufen
Kaufen
Arcutis Biotherapeutics Inc. Chart
stock3 TerminalDu willst selbst ins Charting einsteigen?
Nutze das Charting-Widget auf dem stock3 Terminal für Deine eigene Analyse. Mehr Features. Mehr Werkzeuge. Mehr stock3.
Chart im Terminal öffnen
Arcutis Biotherapeutics Inc. Realtime-Kurs
| Name | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
|---|---|---|---|---|---|---|
| Nasdaq | VK | |||||
| Nasdaq Basic | VK | |||||
| Cboe BZX | VK |
Passende Produkte
| WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
|---|
Keine Ergebnisse gefunden
Wertentwicklung (Nasdaq)
6,24 %
Intraday
10,46 %
1 Woche
47,83 %
1 Monat
364,09 %
Seit Jahresbeginn
406,42 %
1 Jahr
-25,42 %
3 Jahre
Wikifolio
Passender Service zu Arcutis Biotherapeutics Inc.
Webinar zu Arcutis Biotherapeutics Inc.
Kursinformationen (Nasdaq)
- Tagestief / Hoch ($)-
- 52W-Tief / Hoch ($)2,600-15,790
- Jahrestief / Hoch ($)3,070-15,790
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von Arcutis Biotherapeutics Inc.
Keine Dividenden verfügbar
Termine von Arcutis Biotherapeutics Inc.
- Mär4Arcutis Biotherapeutics Inc.Q4 2024 Earnings Release
- Mai20Arcutis Biotherapeutics Inc.Q1 2025 Earnings Release
- Aug13Arcutis Biotherapeutics Inc.Q2 2025 Earnings Release
Beschreibung
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
